Sittner & Nelson LLC Has $225,000 Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Sittner & Nelson LLC increased its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 62.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,085 shares of the medical equipment provider’s stock after buying an additional 801 shares during the period. Sittner & Nelson LLC’s holdings in Zimmer Biomet were worth $225,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Crewe Advisors LLC acquired a new position in Zimmer Biomet during the 1st quarter worth about $31,000. Bangor Savings Bank bought a new stake in Zimmer Biomet during the 3rd quarter worth about $31,000. Family Firm Inc. bought a new stake in Zimmer Biomet during the 2nd quarter worth about $33,000. J.Safra Asset Management Corp raised its holdings in Zimmer Biomet by 712.1% during the 1st quarter. J.Safra Asset Management Corp now owns 268 shares of the medical equipment provider’s stock worth $35,000 after purchasing an additional 235 shares during the last quarter. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA bought a new stake in Zimmer Biomet during the 2nd quarter worth about $43,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

Shares of ZBH opened at $108.69 on Friday. The stock has a market capitalization of $21.64 billion, a P/E ratio of 20.66, a P/E/G ratio of 2.02 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a twelve month low of $101.47 and a twelve month high of $133.90. The company has a 50 day moving average of $106.64 and a 200-day moving average of $110.58. The company has a quick ratio of 0.70, a current ratio of 1.36 and a debt-to-equity ratio of 0.38.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, meeting the consensus estimate of $1.74. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The business had revenue of $1.82 billion during the quarter, compared to analysts’ expectations of $1.80 billion. During the same period last year, the business earned $1.65 earnings per share. The firm’s revenue was up 4.1% on a year-over-year basis. As a group, equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, October 31st. Investors of record on Monday, September 30th were paid a $0.24 dividend. The ex-dividend date of this dividend was Monday, September 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.88%. Zimmer Biomet’s dividend payout ratio is presently 18.25%.

Analysts Set New Price Targets

ZBH has been the subject of several recent research reports. TD Cowen dropped their price objective on Zimmer Biomet from $143.00 to $119.00 and set a “hold” rating for the company in a report on Friday, September 6th. Truist Financial upped their price target on Zimmer Biomet from $112.00 to $117.00 and gave the company a “hold” rating in a research note on Friday, November 1st. Robert W. Baird lowered their price target on Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating for the company in a research note on Thursday, August 8th. Royal Bank of Canada upped their price target on Zimmer Biomet from $120.00 to $125.00 and gave the company an “outperform” rating in a research note on Monday. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a research note on Thursday, October 31st. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $124.11.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.